Company intelligence / Profile preview
InMed Pharmaceuticals Inc.
Vancouver, British Columbia, Canadainmedpharma.com ↗
- Ownership
- Public · INM
- Employees
- ~13
- Development stage
- Phase 2
01
Overview
InMed has completed a Phase 2 clinical trial for INM-755 in epidermolysis bullosa. The company is also developing preclinical programs for Alzheimer's disease and age-related macular degeneration. Recent research demonstrated cannabinol's anti-inflammatory effects for treating skin diseases.
- Therapeutic areas
- OphthalmologyDermatologyNeurology
- Modalities
- Small moleculesCannabinoidsCannabinoid analogs
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Financials
- Market cap
- $7.3M
- Total revenue
- $3.2B
- Enterprise value
- $-1.1B
Beyond the preview
Go deeper on InMed Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InMed Pharmaceuticals Inc..